Article Information
History
- September 14, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- Scott Burkholz1,†,
- Michael Rubsamen2,†,
- Luke Blankenberg3,
- Richard T. Carback III1,
- Daria Mochly-Rosen4 and
- Paul E. Harris1,5,*
- 1Flow Pharma, Inc., Warrensville Heights, OH, USA
- 2Case Western Reserve University, Cleveland, OH, USA
- 3Texas A&M University, College Station, TX, USA
- 4Stanford University School of Medicine, Department of Chemical and Systems Biology, Stanford, CA, USA
- 5Columbia University, Department of Medicine, College of Physicians and Surgeons, NY, USA
- ↵*Corresponding Author Paul Harris, PhD, Columbia University, Department of Medicine, College of Physicians and Surgeons, 650 West 168th Street, New York, NY, USA 10032, Email: peh1{at}columbia.edu
↵† These authors contributed equally to this work and share first authorship
Contributions
Project Design: S.B., M.R., L.B.
Data Analysis, Visualization, and Manuscript Writing: S.B., M.R., L.B., R.T.C., D.M.-R., P.E.H.
Posted September 14, 2022.
Increasing Cases of SARS-CoV-2 Omicron Reinfection Reveals Ineffective Post-COVID-19 Immunity in Denmark and Conveys the Need for Continued Next-Generation Sequencing
